MarketCapExport financials
Sangamo Therapeutics (SGMO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Sangamo Therapeutics Income Statement 2025-2008 | SGMO
Brief overview of financial performance at Sangamo Therapeutics
The conclusions below are based on five years of reported results. Sangamo Therapeutics reported revenue of $118 million in 2020 and $39.6 million by 2025. Across the full period, sales moved by −66.5%; the average annual rate was −19.7%. Revenue ended the period on a sustained downward trend.
The five-year EBITDA result moved by −0.9%: from −$116 million to −$117 million. EBITDA grew faster than revenue, indicating positive operating leverage. EBITDA margin moved from −98.3% to −296.5%. Operating return per unit of revenue declined.
The net financial result changed from −$121 million to −$123 million. The period ended with a larger loss than it began with.
The market value of the business moved from $1.8 billion to $86.9 million, or −95.3%. The financial trend was stronger than the market valuation.
Conclusion
The financial trajectory is weak and requires a cautious interpretation. The strongest signals are stable net income. The weaker side of the profile includes limited revenue growth, a declining EBITDA margin and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Sangamo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
86.9 M | 62.5 M | 138 M | 122 M | 1.08 B | 1.84 B | 809 M | 1.12 B | 1.64 B | 250 M | 422 M | 857 M | 1.11 B | 503 M | 167 M | 194 M | - | - |
Shares |
280 M | 202 M | 174 M | 154 M | 145 M | 134 M | 112 M | 96.9 M | 78.1 M | 70.6 M | 69.8 M | 67 M | 56 M | 52.7 M | 50.5 M | 45.2 M | - | - |
Historical Prices |
0.31 | 0.31 | 0.79 | 0.79 | 7.5 | 15.6 | 8.37 | 11.5 | 16.4 | 3.05 | 9.13 | 15.2 | 13.9 | 6.01 | 2.84 | 4.29 | 3.9 | 10.2 |
Net Income |
-123 M | -97.9 M | -258 M | -192 M | -178 M | -121 M | -95.2 M | -68.3 M | -54.6 M | -71.7 M | -40.7 M | -26.4 M | -26.6 M | -22.3 M | -35.8 M | -24.9 M | -18.6 M | - |
Revenue |
39.6 M | 57.8 M | 176 M | 111 M | 111 M | 118 M | 102 M | 84.5 M | 36.6 M | 19.4 M | 39.5 M | 45.9 M | 24.1 M | 21.7 M | 10.3 M | 20.8 M | 22.2 M | - |
Gross Profit |
- | - | - | - | - | 118 M | - | - | - | - | 39.5 M | 45.9 M | 24.1 M | 21.7 M | 10.3 M | - | - | - |
Operating Income |
-121 M | -104 M | -274 M | -201 M | -183 M | -130 M | -105 M | -77.2 M | -56.4 M | -72.6 M | -46.9 M | -26.8 M | -26.7 M | -22.2 M | -35.8 M | -24.9 M | -19.4 M | - |
Interest Expense |
-3.56 M | 4.35 M | - | - | - | - | - | - | - | 887 K | 431 K | 364 K | 82 K | - | - | - | 268 K | - |
EBITDA |
-117 M | -98.9 M | -259 M | -189 M | -174 M | -116 M | -95.6 M | -74.8 M | -54.9 M | -71.6 M | -45.9 M | -26 M | -26.1 M | -21.5 M | -35.2 M | -24.3 M | -18.8 M | - |
Operating Expenses |
161 M | 162 M | 450 M | 313 M | 294 M | 248 M | 208 M | 162 M | 92.9 M | 91.9 M | 86.4 M | 72.4 M | 50.8 M | 43.9 M | 46.1 M | 45.7 M | 41.6 M | - |
General and Administrative Expenses |
34.9 M | 44.7 M | 61.2 M | 62.7 M | 63.2 M | 67.1 M | 61.7 M | 46.7 M | 27.2 M | 26.3 M | 19.2 M | 15.7 M | 13.8 M | 12.1 M | - | 12.6 M | 12.6 M | - |
All numbers in USD currency
Quarterly Income Statement Sangamo Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
390 M | 304 M | 257 M | 220 M | 208 M | 204 M | 180 M | 177 M | 174 M | 169 M | - | 158 M | 148 M | 146 M | 146 M | 145 M | 144 M | 143 M | 142 M | 141 M | 139 M | 116 M | 116 M | 116 M | 114 M | 102 M | 102 M | 102 M | 97.3 M | 86.3 M | 85.6 M | 83.8 M | 72.5 M | 71 M | 70.9 M | 70.6 M | 70.5 M | 70.4 M | 70.4 M | 69.9 M | 69.7 M | 69.3 M | 69.1 M | 68.2 M | 68 M | 63.2 M | 62.2 M | 54.8 M | 53.8 M | 53.4 M | 53.1 M | 52.8 M | 52.7 M | 52.6 M | 52.6 M | 52.5 M | 51.5 M | 52.6 M |
Net Income |
-31 M | -34.9 M | -20 M | -30.6 M | 10.7 M | -36.1 M | -49.1 M | -104 M | -115 M | 21.1 M | - | -53.2 M | -43.2 M | -44 M | - | -47.7 M | -47.2 M | -45.9 M | -40.6 M | -1.55 M | -35.9 M | -42.9 M | 4.56 M | -27.3 M | -30.3 M | -42.2 M | -18.7 M | -12.8 M | -16.6 M | -20.2 M | -13.1 M | -12.4 M | -12.5 M | -16.6 M | -9.62 M | -19 M | -26.6 M | -16.5 M | -14 M | -9.24 M | -12.1 M | -5.32 M | -4.32 M | -7.54 M | -6.98 M | -7.57 M | -8.14 M | -6.14 M | -5.45 M | -6.88 M | -3.48 M | -5.79 M | -5.73 M | -7.27 M | -6.36 M | -9.55 M | -10.3 M | -9.58 M |
Revenue |
1.44 M | 581 K | 18.3 M | 6.44 M | 49.4 M | 356 K | 481 K | 9.4 M | 6.84 M | 158 M | - | 26.5 M | 29.4 M | 28.2 M | - | 28.6 M | 27.9 M | 26.3 M | 25.8 M | 57.8 M | 21.6 M | 13.1 M | 54.9 M | 22 M | 17.5 M | 8.07 M | 26.8 M | 23.6 M | 21.4 M | 12.6 M | 13.1 M | 11.8 M | 8.25 M | 3.42 M | 8.92 M | 2.82 M | 3.7 M | 3.94 M | 9.12 M | 8.57 M | 8.36 M | 13.5 M | 15 M | 12.4 M | 10.4 M | 8.12 M | 6.87 M | 5.71 M | 6.93 M | 4.62 M | 8.93 M | 4.91 M | 4.57 M | 3.24 M | 4.75 M | 1.86 M | 1.51 M | 2.2 M |
Operating Income |
-31.9 M | -35.6 M | -17.9 M | -29.6 M | 10.6 M | -37.1 M | -51.5 M | -106 M | -124 M | 18 M | - | -54.9 M | -45.7 M | -45.3 M | - | -48.4 M | -48.7 M | -46.3 M | - | -3.7 M | -37.9 M | -44.5 M | - | -29.2 M | -33.5 M | -43.9 M | - | -16.2 M | -19.1 M | -21 M | - | -13 M | -12.8 M | -16.8 M | - | -19.2 M | -26.8 M | -16.7 M | - | -12.7 M | -12.3 M | -6.22 M | - | -7.65 M | -7.05 M | -7.61 M | - | -6.16 M | -5.47 M | -6.9 M | - | -5.8 M | -5.74 M | -7.28 M | - | -9.57 M | -10.3 M | -9.6 M |
Interest Expense |
651 K | 107 K | -2.49 M | -1.16 M | -221 K | 614 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-31.2 M | - | - | -28.6 M | - | - | -50.1 M | - | - | 21.5 M | - | -46.1 M | -45.7 M | -42.4 M | - | -41.8 M | -48.7 M | -44.4 M | - | 298 K | -35.3 M | -43.2 M | - | -26.5 M | -31.9 M | -43.2 M | - | -14.6 M | -17.9 M | -20.4 M | - | -12 M | -12.2 M | -16.5 M | - | -18.5 M | -26.3 M | -16.4 M | - | -11.9 M | -11.8 M | -6.07 M | - | -7.25 M | -6.8 M | -7.49 M | - | -5.71 M | -5.16 M | -6.76 M | - | -5.3 M | -5.41 M | -7.12 M | - | -9.1 M | -9.96 M | -9.44 M |
Operating Expenses |
33.4 M | 36.1 M | 36.2 M | 36.1 M | 38.8 M | 37.4 M | 52 M | 116 M | 130 M | 140 M | - | 81.4 M | 75.1 M | 73.5 M | - | 77 M | 76.6 M | 72.6 M | 69.2 M | 61.5 M | 59.4 M | 57.6 M | 53.4 M | 51.2 M | 51.1 M | 52 M | 47.6 M | 39.8 M | 40.6 M | 33.6 M | 26.8 M | 24.8 M | 21 M | 20.2 M | 18.8 M | 22 M | 30.5 M | 20.6 M | 24.8 M | 21.3 M | 20.6 M | 19.7 M | 19.4 M | 20.1 M | 17.4 M | 15.7 M | 15 M | 11.9 M | 12.4 M | 11.5 M | 12.3 M | 10.7 M | 10.3 M | 10.5 M | 11.1 M | 11.4 M | 11.8 M | 11.8 M |
General and Administrative Expenses |
6.82 M | 7.99 M | 9.08 M | 10.1 M | 11 M | 12 M | 11.8 M | 13.9 M | 16 M | 18.1 M | - | 16.2 M | 15.1 M | 14.9 M | - | 14.5 M | 16.5 M | 16.1 M | - | 16.2 M | 17.9 M | 16.1 M | - | 14.9 M | 14.6 M | 17.1 M | - | 11 M | 11.3 M | 10.1 M | - | 6.42 M | 6.04 M | 7.28 M | - | 5.02 M | 11.1 M | 5.36 M | - | 4.56 M | 5.02 M | 4.73 M | - | 3.73 M | 3.97 M | 3.64 M | - | 3.16 M | 3.12 M | 3.31 M | - | 3.14 M | 2.74 M | 3.24 M | - | 3.59 M | 3.68 M | 3.54 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Sangamo Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Russia
Canada
Israel
Britain
Singapore
China
Schweiz
